Evidence map›Paper›PMID 35465165›Full record

ArticleComputational and structural biotechnology journal2022

Human gut metatranscriptome changes induced by a fermented milk product are associated with improved tolerance to a flatulogenic diet.

Iñigo Oyarzun, Boris Le Nevé, Francisca Yañez, Zixuan Xie, Matthieu Pichaud, Gerard Serrano-Gómez, Joaquim Roca, Patrick Veiga, Fernando Azpiroz, Julien Tap and 1 more

Open access · goldAbstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Iñigo OyarzunMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Boris Le NevéDanone Nutricia Research, Palaiseau, France.
Francisca YañezMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Zixuan XieMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Matthieu PichaudDanone Nutricia Research, Palaiseau, France.
Gerard Serrano-GómezMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Joaquim RocaMolecular Biology Institute of Barcelona (IBMB), Spanish National Research Council (CSIC), Barcelona, Spain.
Patrick VeigaDanone Nutricia Research, Palaiseau, France.
Fernando AzpirozMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Julien TapDanone Nutricia Research, Palaiseau, France.
Chaysavanh ManichanhMicrobiome Lab, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Vall d'Hebron Institut de Recerca · ESDanone (France) · FRConsejo Superior de Investigaciones Científicas · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Healthy plant-based diets rich in fermentable residues may induce gas-related symptoms, possibly mediated by the gut microbiota. We previously showed that consumption of a fermented milk product (FMP) containing Bifidobacterium animalis subsp. lactis CNCM I-2494 and lactic acid bacteria improved gastrointestinal (GI) comfort in response to a flatulogenic dietary challenge in healthy individuals. To study the effects of the FMP on gut microbiota activity from those participants, we conducted a metatranscriptomic analysis of fecal samples (n = 262), which were collected during the ingestion of a habitual diet and two series of a 3-day high-residue challenge diet, before and following 28-days of FMP consumption. Most of the FMP species were detected or found enriched upon consumption of the product. FMP mitigated the effect of a flatulogenic diet on gas-related symptoms in several ways. First, FMP consumption was associated with the depletion of gas-producing bacteria and increased hydrogen to methane conversion. It also led to the upregulation of activities such as replication and downregulation of functions related to motility and chemotaxis. Furthermore, upon FMP intake, metabolic activities such as carbohydrate metabolism, attributed to B. animalis and S. thermophilus, were enriched; these activities were coincidentally found to be negatively associated with several GI symptoms. Finally, a more connected microbial ecosystem or mutualistic relationship among microbes was found in responders to the FMP intervention. Taken together, these findings suggest that consumption of the FMP improved the tolerance of a flatulogenic diet through active interactions with the resident gut microbiota.

Indexed as

Bifidobacterium animalis subsp. lactis CNCM I-2494/DN-173010Fermented milk productGut microbiotaGut symptomsIntestinal gasMetatranscriptomics

Identifiers

PMID35465165
PMCPMC9014321
OpenAlexW4223898223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.